Abstract | INTRODUCTION: PATIENTS AND METHODS: We compared LV systolic and diastolic function in inactive patients with acromegaly (n = 22), who were divided into patients with long-term control by octreotide (n = 14) and patients with long-term cure by surgery/ radiotherapy (n = 8). We also assessed these parameters in patients with active acromegaly (n = 17). RESULTS: In patients with active acromegaly, systolic function at rest was decreased by 18% (P < 0.01), LV mass index increased by 40% (P < 0.04) and isovolumetric relaxation time increased by 19% (P < 0.01), compared with patients with inactive acromegaly. These parameters were not different between well-controlled and cured patients. Using tissue Doppler imaging, the ratio between early and late diastolic velocity (E'/A' ratio) was decreased in active, compared with inactive acromegaly (0.75+/-0.07 versus 1.24+/-0.15; P < 0.01). This E'/A' ratio was considerably higher in cured, compared with octreotide-treated, patients (1.75+/-0.41 versus 1.05+/-0.1; P < 0.01). CONCLUSION: Diastolic function is persistently and significantly more impaired in acromegalic patients with long-term control by octreotide than in surgically cured patients, which points to biological effects of subtle abnormalities in growth hormone secretion. Criteria for strict biochemical control of acromegaly should thus be reconsidered.
|
Authors | S W van Thiel, J J Bax, N R Biermasz, E R Holman, D Poldermans, F Roelfsema, H J Lamb, E E van der Wall, J W A Smit, J A Romijn, A M Pereira |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 153
Issue 2
Pg. 231-8
(Aug 2005)
ISSN: 0804-4643 [Print] England |
PMID | 16061829
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Human Growth Hormone
- Octreotide
|
Topics |
- Acromegaly
(complications, drug therapy, surgery)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Diastole
- Echocardiography, Doppler
- Female
- Human Growth Hormone
(metabolism)
- Humans
- Male
- Middle Aged
- Octreotide
(administration & dosage)
- Systole
- Treatment Outcome
- Ventricular Dysfunction, Left
(diagnostic imaging, etiology)
|